datetime,headline,summary,related,lang,source
2020-12-01 09:08:06-05:00,Kadmon Holdings (KDMN) Receives a Buy from Oppenheimer,"In a report issued on December 10, Mark Breidenbach from Oppenheimer maintained a Buy rating on Kadmon Holdings (KDMN), with a price target of $8.00. The",KDMN,en,Smarter Analyst
2020-11-24 08:00:00-05:00,Kadmon to Host Virtual Key Opinion Leader Event at the 62nd ASH Annual Meeting,"NEW YORK, NY / ACCESSWIRE / November 24, 2020 / Kadmon Holdings, Inc.",KDMN,en,Yahoo Finance
2020-10-21 14:58:44-05:00,Kadmon (NYSE:KDMN) Shares Down 7.8%,"Shares of Kadmon Holdings Inc (NYSE:KDMN) traded down 7.8% on Wednesday . The company traded as low as $3.41 and last traded at $3.42. 2,904,642 shares traded hands during mid-day trading, an increase of 26% from the average session volume of 2,301,143 shares. The stock had previously closed at $3.71. A number of research analysts […]",KDMN,en,The Olympia Report
2020-10-21 05:54:41-05:00,"Kadmon Holdings Inc (NYSE:KDMN) Expected to Post Quarterly Sales of $530,000.00","Brokerages expect Kadmon Holdings Inc (NYSE:KDMN) to announce sales of $530,000.00 for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for Kadmon’s earnings, with the lowest sales estimate coming in at $230,000.00 and the highest estimate coming in at $960,000.00. Kadmon posted sales of $230,000.00 in the same quarter last […]",KDMN,en,Stock Observer
2020-09-17 13:26:04-05:00,Kadmon Holdings (KDMN) Investor Presentation - Slideshow (NYSE:KDMN),"The following slide deck was published by Kadmon Holdings, Inc. in conjunction with this event..",KDMN,en,Seeking Alpha
2019-12-26 12:01:09-05:00,Kadmon : and Meiji Announce Collaboration to Develop and Commercialize KD025 in Japan | MarketScreener,"Kadmon and Meiji Announce Collaboration to Develop and Commercialize KD025 in Japan NEW YORK and TOKYO December 26, 2019 - Kadmon Holdings, Inc. , a New York-based… | December 26, 2019",KDMN,en,MarketScreener
2019-12-13 08:10:02-05:00,"The Daily Biotech Pulse: Second Time's The Charm For Sarepta, Pfizer's Xeljanz Snags Third Approval, NewLink Genetics Rejects Competing Offer","The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Dec. 12.) Allergan plc (NYSE: AGN ) Amgen, Inc. (NASDAQ: AMGN ) (received approval for its bone-building osteoporosis drug in the U.S.) Aprea Therapeutics Inc (NASDAQ: APRE ) Aptose Biosciences Inc (NASDAQ: APTO ) Aurinia Pharmaceuticals Inc (NASDAQ: AUPH ) Avenue Therapeutics Inc (NASDAQ: ATXI ) (submitted the NDA for intravenous tramadol for the management of moderate to moderately severe pain in adults in a medically supervised health care setting) Bausch Health Companies Inc (NYSE: BHC ) (reacted to upgrade to Overweight rating by JPMorgan) BioNTech SE – ADR (NASDAQ: BNTX ) Bio-Rad Laboratories, Inc. Class A (NYSE: BIO ) Boston Scientific Corporation (NYSE: BSX ) Bristol-Myers Squibb Co (NYSE: BMY ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) Eidos Therapeutics Inc (NASDAQ: EIDX ) ESSA Pharma Inc (NASDAQ: EPIX ) Flexion Therapeutics Inc (NASDAQ: FLXN ) Forty Seven Inc (NASDAQ: FTSV ) Globus Medical Inc (NYSE: GMED ) (reacted to upgrade to Overweight by Wells Fargo Securities) Gossamer Bio Inc (NASDAQ: GOSS ) Hologic, Inc.",KDMN,en,Benzinga Feeds
2019-12-12 07:38:44-05:00,"The Daily Biotech Pulse: European Nod For Amgen, miRagen Overhauls Clinical Pipeline, Tonix Snags Patent Win","Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 11) Acceleron Pharma Inc (NASDAQ: XLRN ) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Aprea Therapeutics Inc (NASDAQ: APRE ) Aptose Biosciences Inc (NASDAQ: APTO ) argenx SE – ADR (NASDAQ: ARGX ) ArQule, Inc. (NASDAQ: ARQL ) Arvinas Inc (NASDAQ: ARVN ) Audentes Therapeutics Inc (NASDAQ: BOLD ) Axsome Therapeutics Inc (NASDAQ: AXSM ) Avadel Pharmaceuticals PLC (NASDAQ: AVDL ) Bausch Health Companies Inc (NYSE: BHC ) BioNTech SE – ADR (NASDAQ: BNTX ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Bristol-Myers Squibb Co (NYSE: BMY ) Cue Biopharma Inc (NASDAQ: CUE ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) Eidos Therapeutics Inc (NASDAQ: EIDX ) Flexion Therapeutics Inc (NASDAQ: FLXN ) Forty Seven Inc (NASDAQ: FTSV ) GlaxoSmithKline plc (NYSE: GSK ) Gossamer Bio Inc (NASDAQ: GOSS ) Immunomedics, Inc. (NASDAQ: IMMU ) Incyte Corporation (NASDAQ: INCY ) IVERIC bio Inc (NASDAQ: ISEE ) Kadmon Holdings Inc (NYSE: KDMN ) Ra Pharmaceuticals Inc (NASDAQ: RARX ) Repro-Med Systems, Inc.",KDMN,en,Benzinga
2019-12-10 07:56:02-05:00,"The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy $3M In ContraFect Shares","The following are top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 9.) Acceleron Pharma Inc (NASDAQ: XLRN ) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Aptose Biosciences Inc (NASDAQ: APTO ) (moved on ASH presentation) argenx SE – ADR (NASDAQ: ARGX ) ArQule, Inc. (NASDAQ: ARQL ), which agreed to be bought by Merck & Co., Inc. (NYSE: MRK ) Arvinas Inc (NASDAQ: ARVN ) Avadel Pharmaceuticals PLC (NASDAQ: AVDL ) Bausch Health Companies Inc (NYSE: BHC ) BioNTech SE – ADR (NASDAQ: BNTX ) BridgeBio Pharma Inc (NASDAQ: BBIO ) (appointed oncology scientist Eli Wallace as chief scientific officer for its oncology programs) Bristol-Myers Squibb Co (NYSE: BMY ) (reacted to ASH presentation) Constellation Pharmaceuticals Inc (NASDAQ: CNST ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) Eidos Therapeutics Inc (NASDAQ: EIDX ) Epizyme Inc (NASDAQ: EPZM ) (reacted to ASH presentation) Flexion Therapeutics Inc (NASDAQ: FLXN ) Forty Seven Inc (NASDAQ: FTSV ) (reacted to ASH presentation) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Global Blood Therapeutics Inc (NASDAQ: GBT ) Globus Medical Inc (NYSE: GMED ) Immunomedics, Inc.",KDMN,en,Benzinga
2019-12-01 22:36:00-05:00,"Kadmon Holdings' (KDMN) Rocking, Will The Rally Continue?",Shares of Kadmon Holdings Inc. (KDMN) have gained an impressive 53% over the last 1 month..,KDMN,en,RTT News
2019-11-16 20:46:07-05:00,Kadmon (NYSE:KDMN) PT Raised to $10.00 at Cantor Fitzgerald,"Kadmon (NYSE:KDMN) had its price objective hoisted by Cantor Fitzgerald from $8.00 to $10.00 in a report published on Tuesday, The Fly reports. They currently have an overweight rating on the stock. Other research analysts have also recently issued reports about the stock. ValuEngine upgraded shares of Kadmon from a sell rating to a hold […]",KDMN,en,Modern Readers
2019-11-15 18:41:27-05:00,"Kadmon Holdings Inc to Post FY2021 Earnings of ($0.53) Per Share, Oppenheimer Forecasts (NYSE:KDMN)","Kadmon Holdings Inc (NYSE:KDMN) – Oppenheimer lowered their FY2021 earnings per share (EPS) estimates for Kadmon in a research note issued on Tuesday, November 12th. Oppenheimer analyst M. Breidenbach now anticipates that the company will earn ($0.53) per share for the year, down from their prior forecast of ($0.42). Oppenheimer also issued estimates for Kadmon’s […]",KDMN,en,Modern Readers
2019-11-12 10:16:00-05:00,Kadmon biopharma shares rise on interim trial results,"Shares of Kadmon Holdings are up about 10% after the New York-based biopharmaceutical company said its treatment for certain patients with chronic graft-versus-host disease met the primary endpoint in a trial. Chronic graft-versus-host disease is a rare condition that can occur after a transplant. Kadmon said it expects to file the experimental therapy with the U.S. Food and Drug Administration next year. Its stock is up 58.65% year-to-date, while the S&P 500 has gained 23%. While the ORR endpoint was met at the interim analysis, the primary analysis of the KD025-213 study will occur in the first quarter of 2020, six months after completion of enrollment. This analysis will include updated safety data and efficacy data, including ORRs and secondary endpoints, such as duration of response, changes in corticosteroid dose and changes in quality of life. Kadmon plans to submit results from the KD025-213 study for presentation at an upcoming scientific meeting.",KDMN,en,Yahoo Finance
2019-11-11 20:26:54-05:00,Kadmon (NYSE:KDMN) Cut to Hold at Zacks Investment Research,"Zacks Investment Research downgraded shares of Kadmon (NYSE:KDMN) from a buy rating to a hold rating in a research report released on Thursday morning, Zacks.com reports. According to Zacks, “Kadmon Holdings, Inc. is a biopharmaceutical company. It engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of significant […]",KDMN,en,Modern Readers
2019-11-11 16:24:00-05:00,Kadmon Announces that KD025 Met Primary Endpoint at Interim Analysis of Pivotal Trial in Chronic Graft-Versus-Host Disease,"NEW YORK / ACCESSWIRE / November 11, 2019 / Kadmon Holdings, Inc. (KDMN) today announced positive topline results from the planned interim analysis of ROCKstar (KD025-213), the fully enrolled pivotal trial evaluating KD025 in patients with chronic graft-versus-host disease (cGVHD) who have received at",KDMN,en,Yahoo Finance
2019-11-08 10:57:21-05:00,"Hedge Funds Have Never Been More Bullish On Kadmon Holdings, Inc (KDMN)","It was a rough fourth quarter for many hedge funds, which were naturally unable to overcome the big dip in the broad market, as the S&P 500 fell by about 4.8% during 2018 and average hedge fund losing about 1%. The Russell 2000, composed of smaller companies, performed even worse, trailing the S&P by",KDMN,en,Yahoo Finance
2019-11-07 16:15:00-05:00,Kadmon Establishes Strategic Partnership with BioNova to Develop and Commercialize KD025 for the Treatment of GVHD in China,"NEW YORK, NY / ACCESSWIRE / November 7, 2019 / Kadmon Holdings, Inc. (KDMN) today announced a strategic partnership with BioNova Pharmaceuticals Ltd. (BioNova) to form a joint venture to exclusively develop and commercialize KD025 for the treatment of graft-versus-host disease (GVHD) in the People'",KDMN,en,Yahoo Finance
2019-08-14 03:10:00-05:00,Kadmon (KDMN) Completes Enrollment in KD025 Study for cGVHD,"Kadmon Holdings (KDMN) completes enrollment in the study of its pipeline candidate, KD025, for the treatment of chronic graft-versus-host disease (cGVHD).",KDMN,en,Zacks Investment Research
2019-08-01 09:33:39-05:00,Will Kadmon Holdings (KDMN) Report Negative Q2 Earnings? What You Should Know,Kadmon Holdings (KDMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,KDMN,en,Zacks Investment Research
2019-05-09 16:01:18-05:00,Kadmon reports Q1 results,No summary available.,KDMN,en,Seeking Alpha
2019-04-09 14:39:50-05:00,Kadmon (KDMN) Investor Presentation - Slideshow,No summary available.,KDMN,en,Seeking Alpha
2019-03-07 16:42:05-05:00,"Kadmon misses by $0.25, misses on revenue",No summary available.,KDMN,en,Seeking Alpha
2019-02-26 08:48:53-05:00,Goldman sees 31% upside in Exact Sciences in premarket analyst action,No summary available.,KDMN,en,Seeking Alpha
